To obtain a therapeutic agent for arrhythmia of mammals including atrial fibrillation by making the agent include loratadine.
This therapeutic agent is obtained by including loratadine represented by formula I {ethyl 4-(8-chloro-5,6-dihydro-11-H- benzo[5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate} or its metabolite, e.g. descarboethoxyloratadine represented by formula II or a salt of the loratadine or its metabolite. The effective daily dose of the above therapeutic agent is preferably about 0.5-4.5 mg/kg based on an individual of 70 kg body weight. A pharmaceutical composition is obtained by including 0.1-95% of the compound represented by formula I. The therapeutic agent is useful for treating arrhythmia such as atrial fibrillation and maintaining the normal signal rhythm.
FRIEDRICH TILMAN
SATLER CAROL A
Next Patent: INHIBITOR OF PRODUCTION OF NITRIC OXIDE